Loading...
Loading...
RLMD| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 22.7M |
| Operating I/L | -22.7M |
| Other Income/Expense | 0.7M |
| Interest Income | 1.3M |
| Pretax | -22.0M |
| Income Tax Expense | -1.3M |
| Net Income/Loss | -22.0M |
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of products for the treatment of central nervous system diseases. Their lead product candidate, Esmethadone, is a N-methyl-D-aspartate receptor antagonist currently in Phase 3 clinical trials for the treatment of major depressive disorder in adults. The company's primary focus is on advancing Esmethadone as an adjunctive or monotherapy treatment, positioning it for potential commercialization in the future.
